A recent study reveals rising early-onset colorectal cancer rates, highlighting disparities and the need for improved ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after ...

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

In an interview with Targeted OncologyTM, Massimo Cristofanilli, MD, medical oncologist at the Breast Center at Weill Cornell ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...